Supernus Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>SP</div>
SUPN -- USA Stock  

USD 20.09  0.04  0.20%

Supernus Stock News module provides quick insight into current market opportunities from investing in Supernus Pharmaceuticals. Use historical and current headlines to determine the investment entry and exit points. Many technical investors use Supernus Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly. Additionally, take a look at Supernus Pharmaceuticals Hype Analysis, Supernus Pharmaceuticals Correlation and Supernus Pharmaceuticals Performance.

Search Today's Stock News

 
Refresh
Supernus Pharmaceuticals stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Supernus daily returns and investor perception about the current pice of Supernus Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Bona fide gift to Gregory Patrick of 1120 shares of Supernus Pharmaceuticals subject to Section 16
Filed transaction by Supernus Pharmaceuticals officer. Exempt bona fide gift subject to Rule 16b-3

Supernus insider trading alert for gift of common stock by Gregory Patrick, Sr.VP Chief Financial Officer, on 28th of August 2020. This event was filed by Supernus Pharmaceuticals with SEC on 2020-08-28. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   

Price to Earnings To Growth

Price to Earnings To Growth Comparative Analysis

Supernus Pharmaceuticals is currently under evaluation in price to earnings to growth category among related companies. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Additionally, take a look at Supernus Pharmaceuticals Hype Analysis, Supernus Pharmaceuticals Correlation and Supernus Pharmaceuticals Performance. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.